{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T03:40:27Z","timestamp":1684035627574},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1007\/s11934-007-0033-5","type":"journal-article","created":{"date-parts":[[2007,9,10]],"date-time":"2007-09-10T09:27:21Z","timestamp":1189416441000},"page":"370-372","source":"Crossref","is-referenced-by-count":1,"title":["Male lower urinary tract symptoms: treatment with \u03b1-blockers, 5-\u03b1-reductase inhibitors, antimuscarinics, or a combination"],"prefix":"10.1007","volume":"8","author":[{"given":"Rodney A.","family":"Appell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,9,11]]},"reference":[{"key":"33_CR1","first-page":"519","volume-title":"5th International Consultation on BPH","author":"C. Chatelain","year":"2001","unstructured":"Chatelain C. Denis L, Foo K, et al.: Recommendations of the international scientific committee. In 5th International Consultation on BPH. Plymouth, UK: Health Publication Ltd.; 2001:519\u2013534."},{"key":"33_CR2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","volume":"170","author":"American Urological Association Practice Guidelines Committee.","year":"2003","unstructured":"American Urological Association Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003, 170:530\u2013547.","journal-title":"J Urol"},{"key":"33_CR3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","volume":"60","author":"C.G. Roehrborn","year":"2002","unstructured":"Roehrborn CG, Boyle P, Nickel JC, et al.: Efficacy and safety of a dual inhibitor of 5-a-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:434\u2013441.","journal-title":"Urology"},{"key":"33_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000019919","volume":"36","author":"B. Djavan","year":"1999","unstructured":"Djavan B, Marberger M: A meta-analysis on the efficacy and tolerability of alpha1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999, 36:1\u201313.","journal-title":"Eur Urol"},{"key":"33_CR5","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0022-5347(01)62536-9","volume":"160","author":"H. Lepor","year":"1998","unstructured":"Lepor H, Williford WO, Barry MJ, et al.: The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998, 160:1358\u20131367.","journal-title":"J Urol"},{"key":"33_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","volume":"61","author":"R.S. Kirby","year":"2003","unstructured":"Kirby RS, Roehrborn C, Boyle P, et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003, 61:119\u2013126.","journal-title":"Urology"},{"key":"33_CR7","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"J.D. McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387\u20132398.","journal-title":"N Engl J Med"},{"key":"33_CR8","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","volume":"174","author":"S.A. Kaplan","year":"2005","unstructured":"Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005, 174:2273\u20132276.","journal-title":"J Urol"},{"key":"33_CR9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1464-410X.2006.06068.x","volume":"97","author":"C.G. Roehrborn","year":"2004","unstructured":"Roehrborn CG, Abrams P, Rovner ES, et al.: Efficacy and tolerability of tolterodine extended release in men with overactive bladder and urgency urinary incontinence. BJU Int 2004, 97:1003\u20131006.","journal-title":"BJU Int"},{"key":"33_CR10","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","volume":"296","author":"S.A. Kaplan","year":"2006","unstructured":"Kaplan SA, Roehrborn CG, Rovner, ES, et al.: Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 2006, 296:2319\u20132328.","journal-title":"JAMA"},{"key":"33_CR11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<224::AID-PATH422>3.0.CO;2-K","volume":"189","author":"B. Gradini","year":"1999","unstructured":"Gradini B, Realacci M, Ginepri A, et al.: Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 1999, 189:224\u2013229.","journal-title":"J Pathol"},{"key":"33_CR12","doi-asserted-by":"crossref","unstructured":"Hopps CV, Mulhall JP. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms (LUTS) in men with erectile dysfunction. J Sex Med 2007, In press.","DOI":"10.1111\/j.1743-6109.2006.00259.x"},{"key":"33_CR13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0022-5347(18)33830-8","volume":"175","author":"S.A. Kaplan","year":"2006","unstructured":"Kaplan SA, Gonzalez RR, Ogiste J, et al.: Combination of an alpha-blocker, alfuzosin SR, and a PDE-5 inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms (LUTS) and sexual dysfunction symptoms [abstract 1638]. J Urol 2006, 175:528.","journal-title":"J Urol"},{"key":"33_CR14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0022-5347(18)33828-X","volume":"175","author":"C. Roehrborn","year":"2006","unstructured":"Roehrborn C, McVary K, Kaminetsky J, et al.: The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) [abstract 1636]. J Urol 2006, 175:527.","journal-title":"J Urol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-007-0033-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-007-0033-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-007-0033-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T03:26:18Z","timestamp":1684034778000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-007-0033-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["33"],"URL":"https:\/\/doi.org\/10.1007\/s11934-007-0033-5","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}